The test strips are held in a convenient, plastic dispensing carton. The kits contain a laminated color chart, (2) sample tubes with caps, and (2) 15' test paper rolls that allow for approximately 100 tests per roll. The color chart has color matches at 0, 12.5, 25, and 50ppm (parts per million) of titratable iodine. This kit meets requirements for federal, state, and local health regulations that require users of iodine-based sanitizer solutions to verify their strength with appropriate test kits. For accurate results, store these test strips away from areas with high humidity or where they may be exposed to water before use, as those conditions may compromise results. Additional information Weight 0.13 lbs Quantity 1/Each Length 15 Feet Width 5/32 Inches Test Level 0 - 50 PPM Type Test Kits
Cleveland 115036 Water Quality Test Kit Because this item is not stocked in our warehouse, processing, transit times and stock availability will vary. If you need your items by a certain date, please contact us prior to placing your order. Expedited shipping availability may vary. We cannot guarantee that this item can be cancelled off of the order or returned once it is placed. Additional information Weight 1 lbs Quantity 1/Each Type Water Test Strips
We are suppliers of BEST QUALITY One Touch Test Strip and looking for serious buyers in need of our products, contact with us for more details OneTouch Ultra Blue Diabetic Test Strips provide fast and less painful testing of glucose levels. Designed for use with the OneTouch Ultra Soft Automatic Blood Sampler and OneTouch UltraSoft Lancets, this blood test strip is ideal for diabetic patients who need to monitor their body glucose level at home.
OneTouch Ultra Blue Blood Glucose Test Strips, 50 Ct: Test Strips, Blue Proven accuracy For blood glucose testing with the OneTouch Ultra Family of Meters and the OneTouch Ping Meter Remote. DoubleSure technology automatically checks each sample twice to confirm their result Requires just a speck of blood 1 vial of 50 test strips
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Handheld Glucose, Lipid(TC, TG, HDL, Cal-LDL) Monitoring System The GREENCARE LIPID is an in vitro diagnostic medical device for measurements of total cholesterol, triglycerides, HDL cholesterol in whole blood by colorimetric assay with enzyme reaction. And the GREENCARE LIPID is an in vitro diagnostic medical device that can diagnose diabetes by measuring blood glucose through electrochemical reactions.
Applicable instruments mainly include abi prism 7300, abi prism 7500, abi prism 7700, abi prism 7900, da-7600, line gene, and icycler etc. 48 tests/kit, large package.
We are a manufacturer specialize in rapid immunoassays for the detection of drugs of abuse, fertility hormones, infectious diseases, and more. We has the most comprehensive family of high-quality key products in cassette, dip strip and midstream format to test urine, serum and whole blood specimens. Our key products: 1. Hcg pregnancy tests: detect pregnancy as early as 1 day after the first missed period 2. Lh ovulation tests: detect lh surge for predicting ovulation 3. Drugs of abuse tests: detect amp, bar, bup, bzo, coc, ket, met, mdma, mop, mtd, opi, oxy, pcp, ppx, tca or thc 4. Infectious diseases tests: aid in the detection of hbsag, hbsab, hbeab, hbeag, hbcab, hbv, hcv, hiv, h. Pylori, malaria p.F., tb, dengue, chlamydia and syphilis 5. Tumor marker tests: aid in the detection of fob, psa, afp and cea We offers a variety of services to the medical device industry, including contract product development, technology transfer, oem services, custom assembly, and packaging with private labeling.